Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN 70 30 PEN versus HUMULIN N.
HUMULIN 70/30 PEN vs HUMULIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro and insulin lispro protamine suspension. Insulin lispro lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production. Insulin lispro protamine provides intermediate-acting basal coverage.
Insulin isophane (NPH) is an intermediate-acting insulin that lowers blood glucose by promoting peripheral glucose uptake, especially in muscle and adipose tissue, and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways.
Subcutaneous injection, individualized based on metabolic needs and blood glucose monitoring; typical starting dose for type 1 diabetes: 0.5 to 0.6 units/kg/day in divided doses (usually twice daily with 70% intermediate-acting NPH and 30% regular insulin); for type 2 diabetes: 0.2 units/kg/day initially, adjusted per glycemic response.
0.5-1 unit/kg/day subcutaneously, divided into 2 doses (morning and evening).
None Documented
None Documented
The terminal elimination half-life of insulin in Humulin 70/30 is approximately 1.5 hours for the regular insulin component and 4-6 hours for the NPH component due to protamine suspension, resulting in a prolonged duration of action.
Terminal half-life: 1.5-2.5 hours (subcutaneous); longer in renal impairment.
Insulin is primarily eliminated via renal metabolism and excretion; approximately 30-80% is cleared by the kidneys, with the remainder undergoing hepatic metabolism. Biliary/fecal excretion is negligible (<1%).
Renal: 60-80% as intact insulin; hepatic and renal clearance; negligible biliary/fecal elimination.
Category C
Category C
Human Insulin
Human Insulin